Michael Poch

2.9k total citations
94 papers, 1.1k citations indexed

About

Michael Poch is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Urology. According to data from OpenAlex, Michael Poch has authored 94 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Surgery, 28 papers in Pulmonary and Respiratory Medicine and 23 papers in Urology. Recurrent topics in Michael Poch's work include Bladder and Urothelial Cancer Treatments (56 papers), Urinary and Genital Oncology Studies (30 papers) and Urological Disorders and Treatments (23 papers). Michael Poch is often cited by papers focused on Bladder and Urothelial Cancer Treatments (56 papers), Urinary and Genital Oncology Studies (30 papers) and Urological Disorders and Treatments (23 papers). Michael Poch collaborates with scholars based in United States, Canada and Pakistan. Michael Poch's co-authors include Wade J. Sexton, Philippe E. Spiess, Julio M. Pow‐Sang, Scott M. Gilbert, Kamran Zargar‐Shoshtari, Pranav Sharma, Mayer Fishman, Juan Chipollini, Dominic H. Tang and Jingsong Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Michael Poch

87 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Poch United States	19	727	290	272	238	131	94	1.1k
Thomas Martini Germany	17	579 0.8×	214 0.7×	257 0.9×	167 0.7×	76 0.6×	38	875
Marcus Horstmann Germany	16	725 1.0×	369 1.3×	404 1.5×	195 0.8×	191 1.5×	77	1.3k
Anne Schuckman United States	22	1.4k 2.0×	263 0.9×	532 2.0×	237 1.0×	120 0.9×	115	1.7k
Ottavia D’Oria Italy	24	340 0.5×	87 0.3×	102 0.4×	222 0.9×	119 0.9×	64	1.3k
Kyle A. Richards United States	19	703 1.0×	315 1.1×	406 1.5×	208 0.9×	117 0.9×	76	1.1k
Yasuyuki Kobayashi Japan	18	456 0.6×	359 1.2×	98 0.4×	135 0.6×	159 1.2×	132	964
Sarah Drouin France	19	334 0.5×	547 1.9×	90 0.3×	142 0.6×	252 1.9×	98	1.1k
Ramesh Thurairaja United Kingdom	15	556 0.8×	180 0.6×	291 1.1×	176 0.7×	81 0.6×	63	784
Ronald L. Hrebinko United States	16	551 0.8×	406 1.4×	203 0.7×	115 0.5×	136 1.0×	48	967
K. Kleinschmidt Germany	14	592 0.8×	310 1.1×	374 1.4×	97 0.4×	56 0.4×	43	992

Countries citing papers authored by Michael Poch

Since Specialization

Citations

This map shows the geographic impact of Michael Poch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Poch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Poch more than expected).

Fields of papers citing papers by Michael Poch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Poch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Poch. The network helps show where Michael Poch may publish in the future.

Co-authorship network of co-authors of Michael Poch

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Poch. A scholar is included among the top collaborators of Michael Poch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Poch. Michael Poch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maughan, Benjamin L., Christopher Dechet, Julia Beck, et al.. (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for ImmunoTherapy of Cancer. 13(3). e010572–e010572. 1 indexed citations

Miller, Justin, Hongzhi Xu, Logan Zemp, et al.. (2025). OUTCOMES OF PATIENTS TREATED WITH ADDITIONAL BCG FOLLOWING A BCG UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER DIAGNOSIS. Urologic Oncology Seminars and Original Investigations. 43(3). 84–84. 1 indexed citations

Jazayeri, Seyed Behzad, Facundo Davaro, Hongzhi Xu, et al.. (2025). Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology Oncology. 8(4). 888–892.

Li, Roger, Philippe E. Spiess, Wade J. Sexton, et al.. (2023). Phase Ib neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 41(16_suppl). e16613–e16613. 1 indexed citations

Li, Roger, Wade J. Sexton, Jasreman Dhillon, et al.. (2023). A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clinical Cancer Research. 29(19). 3875–3881. 18 indexed citations

Abrahams, Dominique, Cheryl A. Cox, Matthew Beatty, et al.. (2023). Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer. Frontiers in Immunology. 14. 1275375–1275375. 10 indexed citations

Li, Roger, Wenyi Fan, Kyle Rose, et al.. (2023). Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urologic Oncology Seminars and Original Investigations. 41(11). 457.e17–457.e24. 1 indexed citations

Green, E. Allison, Kyle Rose, Scott M. Gilbert, et al.. (2022). Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4587–4587. 1 indexed citations

Li, Roger, Philippe E. Spiess, Wade J. Sexton, et al.. (2022). Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 40(16_suppl). 4574–4574. 3 indexed citations

10.

Aydın, Ahmet Murat, Richard R. Reich, Biwei Cao, et al.. (2021). Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urologic Oncology Seminars and Original Investigations. 40(4). 164.e1–164.e7. 1 indexed citations

11.

Aydın, Ahmet Murat, Patrick Innamarato, Ali Hajiran, et al.. (2020). Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. Journal for ImmunoTherapy of Cancer. 8(2). e001673–e001673. 7 indexed citations

12.

Kim, Youngchul, Junmin Zhou, Roger Li, et al.. (2020). Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World Journal of Urology. 39(5). 1539–1547. 11 indexed citations

13.

Patel, Sephalie Y., Robert S. Ackerman, David Boulware, & Michael Poch. (2020). Epidural anesthesia may be associated with increased postoperative complications in the elderly population undergoing radical cystectomy: an analysis from the National Surgical Quality Improvement Project (NSQIP) database. World Journal of Urology. 39(2). 433–441. 8 indexed citations

14.

Kumar, Nagi B., Shohreh Dickinson, Michael J. Schell, et al.. (2018). Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 9(102). 37798–37806. 7 indexed citations

15.

Agarwal, Gautum, Pranav Sharma, Hui‐Yi Lin, et al.. (2016). Sociodemographic and Provider Based Disparities in the Management of Stage I Testicular Cancer. Urology Practice. 4(1). 36–42. 3 indexed citations

16.

Poch, Michael, et al.. (2015). Prostate cancer trends in Barbados: An analysis of the Barbados Urologic Diseases Survey database. Cancer Epidemiology. 39(6). 825–830. 2 indexed citations

17.

Russell, Christopher, John Fisher, Gautum Agarwal, et al.. (2015). Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clinical Genitourinary Cancer. 14(1). 89–95. 13 indexed citations

18.

Strom, Tobin J., Richard B. Wilder, Daniel C. Fernandez, et al.. (2014). A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiotherapy and Oncology. 111(1). 126–131. 49 indexed citations

19.

Sharma, Pranav, Kamran Zargar‐Shoshtari, Jamie T. Caracciolo, et al.. (2014). Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World Journal of Urology. 33(10). 1585–1592. 23 indexed citations

20.

Poch, Michael, François I. Luks, Stephen R. Carr, & Monique E. De Paepe. (2005). Intratwin Arteriovenous Fistula of the Placenta in a Case of Twin-to-Twin Transfusion Syndrome. American Journal of Perinatology. 22(1). 3–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact